Abstract:
Solid organ transplant recipients with immunosuppressant regimens to prevent rejection are less able to mount effective immune responses to pathogenic infection. Here, we apply a recently reported mass spectrometry-based serological approach known as Ig-MS to characterize immune responses against infection with SARS-CoV-2 in cohorts of transplant recipients and immunocompetent controls, both at a single early time point following COVID-19 diagnosis as well as over the course of one-month postdiagnosis. We found that the antibody repertoires generated by transplant recipients against SARS-CoV-2 do not differ significantly compared to immunocompetent individuals with regard to repertoire titer, clonality, or glycan composition. Importantly, our study is the first to characterize the evolution of antibody glycan profiles in transplant recipients with COVID-19 disease, presenting evidence that the evolution of glycan composition in these immunocompromised individuals is similar to that in immunocompetent people.
摘要:
使用免疫抑制剂方案以防止排斥反应的实体器官移植受体对病原性感染的有效免疫应答能力较弱。这里,我们应用最近报道的基于质谱的血清学方法,称为Ig-MS,以表征针对感染SARS-CoV-2的免疫应答移植受者和免疫活性对照的队列。无论是在COVID-19诊断后的一个早期时间点,还是在诊断后的一个月内。我们发现,与具有免疫能力的个体相比,针对SARS-CoV-2的移植受者产生的抗体库在库滴度方面没有显着差异,克隆,或聚糖组成。重要的是,我们的研究首次描述了患有COVID-19疾病的移植受体中抗体聚糖谱的演变,提供证据表明,这些免疫功能低下的个体中聚糖组成的演变与免疫功能正常的人相似。